A New Alliance to Improve Military Health Care

Cerner (CERN), Epic, and Allscripts (MDRX) are all ready to battle over a massive $11 billion contract to modernize the Department of Defense electronic health records system.

Jul 5, 2014 at 10:30AM

If the Department of Defense was worried that it wouldn't have any takers on its massive contract to modernize its health-care electronic records system, it shouldn't have been. So far, three teams of companies have announced that they'll make bids to cast aside the DoD's aging and inadequate system and launch a new system that plays nicely across all of the DoD's hospitals and clinics.

The latest companies to report that they'll team up to angle for the contract are Cerner (NASDAQ:CERN), Leidos (NYSE:LDOS), and Accenture (NYSE:ACN).


Source: Secretary of Defense Flickr.

The sheer size of the DoD's contract is staggering
The DoD's contract to replace its disparate system is forecast at $11 billion. To put that into context, the total annual market for electronic health records currently stands at just $10 billion, according to Accenture. Today, hundreds of small niche companies compete to integrate health-care IT systems in practices, hospitals, and long-term care facilities, but a handful of companies, including Cerner, have established themselves as leaders.

Cerner is the second largest provider of EHR software systems to large hospital systems, for example, trailing only the privately held Epic. Even so, the DoD contract would be a boon for the company given that its sales totaled a bit less than $3 billion last year.


Secretary of Defense Flickr

Cerner has a tough battle on its hands.
Epic has teamed up with IBM to provide the system and security support necessary, and because each is a market leader in its industry; they may have an edge in swaying the deal their way.

Allscripts is also vying for the contract through a partnership with government contractor Computer Sciences, and hardware expert Hewlett-Packard. Allscripts is a bit smaller than Epic and Cerner, but it still boasts market share near 10%, and counts 1,500 hospitals as customers.

To outmaneuver those competitors, Cerner has lined up Leidos, which was a recent spinoff of government contractor Science Applications International Corporation, or SAIC, and consulting giant Accenture. Leidos built the DoD's composite health-care system back in 1988 under a $1 billion contract, and that system, known as CHCS, is still in use in some military hospitals. But Leidos' ties to Washington don't end there. The company got nearly 80% of its fiscal 2014 sales from U.S. Government contracts, and gets nearly 70% of its sales either directly or indirectly from the DoD already.


Source: Cerner

Cerner's and Leidos' other partner, Accenture's health and public service segment, is also an important player in Washington and among health-care policy leaders. That business generated more than $1.3 billion in revenue for Accenture in the first quarter, up 10% from last year. Some of that growth came thanks to winning the $90 million contract to repair the troubled Affordable Care Act marketplace in January, a win that may demonstrate its ability to tackle tough projects.

Fool-worthy final thoughts
The DoD is still fact-finding and hasn't officially issued a request for a proposal; however, that request should come soon and, if so, a contract is likely to be awarded next year. Because the contract will be for 10 years, it will represent more than $1 billion in new revenue per year to the winning team.

Even though that money will be split among winning teammates, it will still make a significant impact on Epic, Allscripts, or Cerner. While I'm not putting money into any of these companies yet, I'll be watching them closely during the coming months to see if there are any signals as to who may have an edge.

Leaked: This coming blockbuster could revolutionize health-care IT
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There's a product in development that will revolutionize not only how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns, you'll need The Motley Fool's new free report on the dream team responsible for this game-changing blockbuster. CLICK HERE NOW.

Todd Campbell has no position in any stocks mentioned. Todd owns E.B. Capital Markets, LLC. E.B. Capital's clients may or may not have positions in the companies mentioned. Todd owns Gundalow Advisors, LLC. Gundalow's clients do not have positions in the companies mentioned. The Motley Fool recommends Accenture. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

4 in 5 Americans Are Ignoring Buffett's Warning

Don't be one of them.

Jun 12, 2015 at 5:01PM

Admitting fear is difficult.

So you can imagine how shocked I was to find out Warren Buffett recently told a select number of investors about the cutting-edge technology that's keeping him awake at night.

This past May, The Motley Fool sent 8 of its best stock analysts to Omaha, Nebraska to attend the Berkshire Hathaway annual shareholder meeting. CEO Warren Buffett and Vice Chairman Charlie Munger fielded questions for nearly 6 hours.
The catch was: Attendees weren't allowed to record any of it. No audio. No video. 

Our team of analysts wrote down every single word Buffett and Munger uttered. Over 16,000 words. But only two words stood out to me as I read the detailed transcript of the event: "Real threat."

That's how Buffett responded when asked about this emerging market that is already expected to be worth more than $2 trillion in the U.S. alone. Google has already put some of its best engineers behind the technology powering this trend. 

The amazing thing is, while Buffett may be nervous, the rest of us can invest in this new industry BEFORE the old money realizes what hit them.

KPMG advises we're "on the cusp of revolutionary change" coming much "sooner than you think."

Even one legendary MIT professor had to recant his position that the technology was "beyond the capability of computer science." (He recently confessed to The Wall Street Journal that he's now a believer and amazed "how quickly this technology caught on.")

Yet according to one J.D. Power and Associates survey, only 1 in 5 Americans are even interested in this technology, much less ready to invest in it. Needless to say, you haven't missed your window of opportunity. 

Think about how many amazing technologies you've watched soar to new heights while you kick yourself thinking, "I knew about that technology before everyone was talking about it, but I just sat on my hands." 

Don't let that happen again. This time, it should be your family telling you, "I can't believe you knew about and invested in that technology so early on."

That's why I hope you take just a few minutes to access the exclusive research our team of analysts has put together on this industry and the one stock positioned to capitalize on this major shift.

Click here to learn about this incredible technology before Buffett stops being scared and starts buying!

David Hanson owns shares of Berkshire Hathaway and American Express. The Motley Fool recommends and owns shares of Berkshire Hathaway, Google, and Coca-Cola.We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

©1995-2014 The Motley Fool. All rights reserved. | Privacy/Legal Information